Phase II, randomized, placebo-controlled trial of neoadjuvant celecoxib in men with clinically localized prostate cancer: evaluation of drug-specific biomarkers.
about
Obesity and cancer: mechanistic insights from transdisciplinary studiesCelecoxib plus hormone therapy versus hormone therapy alone for hormone-sensitive prostate cancer: first results from the STAMPEDE multiarm, multistage, randomised controlled trial.A phase II randomized trial of Observation versus stereotactic ablative RadiatIon for OLigometastatic prostate CancEr (ORIOLE)The prognostic value of cyclooxygenase-2 expression in patients with esophageal cancer: evidence from a meta-analysis.Bone marrow fat: linking adipocyte-induced inflammation with skeletal metastasesAnti-cancer effects of celecoxib on nasopharyngeal carcinoma HNE-1 cells expressing COX-2 oncoproteinTumor cells and tumor-associated macrophages: secreted proteins as potential targets for therapy.Lenalidomide modulates IL-8 and anti-prostate antibody levels in men with biochemically recurrent prostate cancer.Celecoxib inhibits growth of human autosomal dominant polycystic kidney cyst-lining epithelial cells through the VEGF/Raf/MAPK/ERK signaling pathwayAspirin use after a prostate cancer diagnosis and cancer survival in a prospective cohort.GLIPR1 tumor suppressor gene expressed by adenoviral vector as neoadjuvant intraprostatic injection for localized intermediate or high-risk prostate cancer preceding radical prostatectomy.Neoadjuvant therapy preceding prostatectomy for prostate cancer: rationale and current trials.Analysis of protein biomarkers in human clinical tumor samples: critical aspects to success from tissue acquisition to analysis.Eicosanoid signalling pathways in the development and progression of colorectal cancer: novel approaches for prevention/intervention.A systematic review of the role of adjuvant and neoadjuvant pharmacotherapy in patients undergoing radical prostatectomy.Systematic review and meta-analysis of COX-2 expression and polymorphisms in prostate cancer.The diet as a cause of human prostate cancer.COX-2 inhibitors arrest prostate cancer cell cycle progression by down-regulation of kinetochore/centromere proteins.Dual antigen target-based immunotherapy for prostate cancer eliminates the growth of established tumors in mice.Regression of prostate tumors upon combination of hormone ablation therapy and celecoxib in vivo.Celecoxib enhances radiosensitivity in medulloblastoma-derived CD133-positive cells.COX-2 inhibitors in prostate cancer treatment--hold your horses?Cell cycle inhibition without disruption of neurogenesis is a strategy for treatment of aberrant cell cycle diseases: an update.Phase II trial of weekly Docetaxel, Zoledronic acid, and Celecoxib for castration-resistant prostate cancer.Cyclooxygenase-2 (COX-2) inhibition for prostate cancer chemoprevention: double-blind randomised study of pre-prostatectomy celecoxib or placebo.
P2860
Q26786829-AB2E8A8B-FE86-4054-B4E0-EDEDB4D609F6Q30521133-C5BA7BC7-B3CC-477F-920A-C43BA04F2F06Q32173730-68C9939F-8388-498B-B683-7C630B318FB9Q33813283-2D60AC05-F93B-49D4-82E1-0BE21A51BFCAQ34132305-A64CA8EF-7037-42F9-909E-05DF32BEDA5DQ34361606-D97AB9D2-87C7-459D-86ED-5A71C4D1E02EQ35582297-10373E19-A3DD-4989-884C-CE2FAB0BBD06Q35641782-40B2CA22-E4A6-466D-86E0-8BB82189B78BQ35981512-B8C41A26-B4AA-465F-A17C-4489F0F70C38Q36478226-6EE0EECC-F6FD-4E51-8607-523F50BEF1B1Q37398588-0FDE7CD0-DBB3-4C12-ABBD-36A88782AA31Q37705424-16377E37-16E3-42BC-8262-9731DE8EE509Q37862749-A339832E-7759-4B42-B5B0-0E2E6A4D6ED2Q37963769-BF64F1A4-302E-4480-AA48-6C88241975BDQ38014525-58387A00-C689-439A-8474-0EE59C669402Q38051084-A8D64DF0-6F47-4CFB-8FDE-9331C8BBA231Q38151527-AF925123-628C-49D7-BA26-E95FC6F74650Q38997789-D544C912-0722-46B5-9A91-2A37EDC4CB3DQ39525614-B1C46E09-CB7F-4D37-B749-4A0A514C75B2Q39566592-EFF7E4B9-B565-4FA8-A06D-9E24C331899CQ39696393-75B87613-8734-4D7A-92A3-BE04BC024E04Q42140641-32B1FE12-8F97-40E0-A453-EFEE810FF0EDQ51604439-F14A3CFC-2A26-4874-86B7-B085EDBEA87CQ53786874-708CFD61-5A66-41C1-9CE1-FE816514C6E3Q53814173-311F6872-5F93-468D-BB1B-73F0F475C408
P2860
Phase II, randomized, placebo-controlled trial of neoadjuvant celecoxib in men with clinically localized prostate cancer: evaluation of drug-specific biomarkers.
description
2009 nî lūn-bûn
@nan
2009 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Phase II, randomized, placebo- ...... n of drug-specific biomarkers.
@ast
Phase II, randomized, placebo- ...... n of drug-specific biomarkers.
@en
Phase II, randomized, placebo- ...... n of drug-specific biomarkers.
@nl
type
label
Phase II, randomized, placebo- ...... n of drug-specific biomarkers.
@ast
Phase II, randomized, placebo- ...... n of drug-specific biomarkers.
@en
Phase II, randomized, placebo- ...... n of drug-specific biomarkers.
@nl
prefLabel
Phase II, randomized, placebo- ...... n of drug-specific biomarkers.
@ast
Phase II, randomized, placebo- ...... n of drug-specific biomarkers.
@en
Phase II, randomized, placebo- ...... n of drug-specific biomarkers.
@nl
P2093
P2860
P50
P921
P356
P1476
Phase II, randomized, placebo- ...... n of drug-specific biomarkers.
@en
P2093
Andrew J Dannenberg
Angelo M De Marzo
Elisabeth I Heath
Emmanuel S Antonarakis
Helen Fedor
Howard L Parnes
Janet R Walczak
Marianna L Zahurak
Michael A Carducci
Robin T Gurganus
P2860
P304
P356
10.1200/JCO.2009.21.9410
P407
P577
2009-08-31T00:00:00Z